ArriVent BioPharma, Inc. (AVBP) · Aug 12, 2026 · Earnings

The cash cushion is intact—but Q2 still missed as pivotal data looms

Miss — Q2 EPS $(1.05) vs published consensus near $(0.99)

ArriVent’s cash position remains substantial, but Q2 EPS missed consensus and operating losses widened ahead of key firmonertinib data.

The quarter missed the only clean benchmark. ArriVent reported a second-quarter net loss of $1.05 per share versus published consensus near $0.99, a roughly $0.06-per-share miss. The loss also widened to $49.9 million from $31.4 million a year earlier, driven by higher research and development and general and administrative spending (Income Statement).

MetricQ2 2026Q2 2025Market comparison
Net loss$(49.9)M$(31.4)M— (Income Statement)
R&D expense$42.3M$27.7M— (Income Statement)
G&A expense$10.4M$5.9M— (Income Statement)
Net loss per share$(1.05)$(0.90)Consensus near $(0.99)
Cash and equivalents$154.7M$45.5M at Dec. 31, 2025— (Balance Sheet)
Short-term investments$218.4M$267.3M at Dec. 31, 2025— (Balance Sheet)

The spending increase reflects pipeline execution, not a new revenue problem. R&D rose 53% year over year in the quarter as ArriVent advanced the FURVENT and ALPACCA pivotal studies and moved ARR-217 into dose optimization. But the company remains pre-revenue in this filing, so the higher cost base flows directly into a larger loss rather than being offset by commercial sales (Income Statement; Company Progress).

The balance sheet keeps the clinical story funded for now. Cash, cash equivalents, and short-term investments totaled approximately $373.1 million at June 30, 2026, up from roughly $312.8 million at year-end despite the first-half net loss. The filing does not provide an explicit cash-runway forecast, so the exact duration cannot be confirmed from this release alone (Balance Sheet; Income Statement).

The real valuation event remains clinical, not quarterly financials. Management highlighted upcoming pivotal topline data from the 398-patient FURVENT study and initial Phase 1 data for ARR-217, but supplied no new dated readout or efficacy result in this filing. That leaves the central investment question unchanged: whether firmonertinib can beat chemotherapy on progression-free survival in EGFR exon 20 insertion disease (Company Progress; FURVENT clinical trial description).

Net read: a modest earnings miss with no offsetting new catalyst. The cash position is reassuring and the pipeline remains active, but neither changes the fact that Q2 came in below the roughly $(0.99) consensus expectation. With no new clinical data or explicit timing upgrade, the filing lands slightly worse than expected rather than materially changing the broader setup.

What to watch next

FURVENT pivotal topline data presentation

Original filing on SEC EDGAR

More ArriVent BioPharma, Inc. news

The cash cushion is intact—but Q2 still missed as pivotal data looms | AVBP Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.